L04AA32 • apremilast • Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants
Apremilast is a medication used in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation by decreasing the production of pro-inflammatory cytokines and increasing levels of anti-inflammatory cytokines.
Apremilast is administered orally in tablet form, usually twice daily. It is often used in patients who do not respond adequately to conventional topical or systemic therapies.
Common side effects include nausea, diarrhea, headache, and weight loss. In rare cases, depression or other mood disorders may occur, requiring careful monitoring.
Apremilast is an important therapeutic option for patients with chronic inflammatory conditions, helping to reduce symptoms and improve their quality of life.
Substance: apremilast
Date of last drug list: 01-09-2024
Commercial code: W70444001
Concentration: 30mg
Pharmaceutical form: film-coated tablets
Quantity: 56
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA
Holder: ADALVO LIMITED - MALTA
Number: 15542/2024/01
Shelf life: 2 years